ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouros, D
Right arrow Articles by Siafakas, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouros, D
Right arrow Articles by Siafakas, N
Eur Respir J 1999; 14: 627-632
Copyright © ERS Journals Ltd 1999

Clinical Trial

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

D Bouros, N Bachlitzanakis, J Kottakis, P Pfister, V Polychronopoulos, E Papadakis, S Constantopoulos, M Froudarakis, L Sichletidis, and N Siafakas

A total of 132 adult asthmatics who were symptomatic on 500 microg x day(-1) inhaled beclomethasone dipropionate (BDP) were studied in an open-label randomized, parallel group, 12 week, clinical trial. The addition of 12 microg formoterol fumarate solution aerosol (pressurized metered dose inhaler) b.i.d. to BDP at a dose of 500 microg x day(-1) was compared with a higher dose of 1,000 microg x day(-1) BDP. Mean morning premedication peak expiratory flow rate (PEF) during the final week of treatment (primary end-point) increased in both groups compared to baseline. The estimated treatment difference of 20.4 L x min(-1) (95% confidence interval 3.2-37.6) after 12 weeks of treatment was statistically significant (p<0.05) in favour of the formoterol/BDP group. The overall mean morning premedication PEF for the entire treatment period was higher in the formotero/BDP group (p=0.002). The overall number of puffs of rescue medication and asthma symptom scores were less in the formotero/BDP group (p<0.01). Safety and tolerability evaluations were satisfactory in both groups. In conclusion, the results suggest that the addition of formoterol fumarate to the existing dose of an inhaled corticosteroid should be considered as an alternative to increasing the dose of inhaled corticosteroid in the inadequately controlled asthmatic.


This article has been cited by other articles:


Home page
 ThoraxHome page
M Masoli, M Weatherall, S Holt, and R Beasley
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma
Thorax, September 1, 2005; 60(9): 730 - 734.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. D. D'Urzo, M. C. De Salvo, A. Ramirez-Rivera, J. Almeida, L. Sichletidis, G. Rapatz, and J. Kottakis
In Patients With COPD, Treatment With a Combination of Formoterol and Ipratropium Is More Effective Than a Combination of Salbutamol and Ipratropium : A 3-Week, Randomized, Double-Blind, Within-Patient, Multicenter Study
Chest, May 1, 2001; 119(5): 1347 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. V. Bourdet and D. Williams
Management Considerations for Chronic Asthma
Journal of Pharmacy Practice, April 1, 2001; 14(2): 108 - 125.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.